| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
DCEBIO targets intermediate conductance calcium-activated potassium (IKCa/KCa3.1) channels as an opener. It activates hIK1 K+ channels and apical membrane Cl- conductance to stimulate Cl- secretion. By opening IKCa/KCa3.1 channels, it enhances potassium efflux, leading to membrane hyperpolarization and modulation of cellular excitability and calcium signaling. DCEBIO is a highly potent activator of Cl- secretion.
|
|---|---|
| ln Vitro |
In vitro, DCEBIO is an extremely potent activator of Cl- secretion in T84 colonic cells. It stimulates Cl- secretion via the activation of hIK1 K+ channels and the activation of an apical membrane Cl- conductance. The compound is an opener of intermediate conductance calcium-activated potassium (SKCa/IKCa) channels. It enhances potassium efflux, leading to membrane hyperpolarization. DCEBIO is insoluble in water and ethanol, but soluble in DMSO at ≥19.7 mg/mL.
|
| ln Vivo |
In vivo, DCEBIO has been studied for its effects on chloride secretion and potassium channel modulation. As an activator of Cl- secretion, it may have potential for studying cystic fibrosis and other chloride channel-related disorders. The compound is a derivative of 1-EBIO. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro electrophysiological assays for DCEBIO involve measuring chloride secretion in T84 colonic cells using Ussing chambers or patch-clamp techniques. Cells are treated with the compound at varying concentrations, and chloride secretion is measured as short-circuit current. hIK1 K+ channel activation is assessed by measuring potassium currents using patch-clamp electrophysiology. Apical membrane Cl- conductance is measured. Assays are performed in appropriate buffer systems with positive controls such as known K+ channel openers.
|
| Cell Assay |
In vitro cell-based assays for DCEBIO are conducted in T84 colonic cells and other epithelial cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Chloride secretion is measured using fluorescent chloride indicators or electrophysiological methods. Potassium channel activity is assessed by measuring potassium flux. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
DCEBIO in vivo studies are conducted in animal models of chloride channel disorders. Animals are treated with DCEBIO via oral administration or injection. Chloride secretion and electrolyte balance are assessed. For cystic fibrosis research, animal models of CFTR dysfunction are used. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biochemical analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
DCEBIO (MW 231.08 g/mol, C9H8Cl2N2O) is a derivative of 1-EBIO. It is insoluble in water and ethanol, but soluble in DMSO at ≥19.7 mg/mL. The compound is an activator of Cl- secretion and an opener of IKCa/KCa3.1 channels. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
DCEBIO is generally well-tolerated in preclinical studies. The compound is a potassium channel opener and Cl- secretion activator with established safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
DCEBIO is a dichlorobenzene.
DCEBIO (5,6-dichloro-1-ethyl-1H-benzo[d]imidazol-2(3H)-one) is a derivative of 1-EBIO and a highly potent activator of Cl- secretion in T84 colonic cells. It stimulates Cl- secretion via activation of hIK1 K+ channels and apical membrane Cl- conductance. The compound is an opener of intermediate conductance calcium-activated potassium channels. Its molecular formula is C9H8Cl2N2O with a molecular weight of 231.08 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C9H8N2OCL2
|
|---|---|
| Molecular Weight |
231.07862
|
| Exact Mass |
230.001
|
| CAS # |
60563-36-2
|
| PubChem CID |
656765
|
| Appearance |
White to light brown solid powder
|
| Density |
1.413g/cm3
|
| Melting Point |
209.5-210.5 °C
|
| Index of Refraction |
1.592
|
| LogP |
2.656
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
14
|
| Complexity |
249
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LKHRMULASXZCLG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H8Cl2N2O/c1-2-13-8-4-6(11)5(10)3-7(8)12-9(13)14/h3-4H,2H2,1H3,(H,12,14)
|
| Chemical Name |
5,6-dichloro-3-ethyl-1H-benzimidazol-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~216.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3275 mL | 21.6375 mL | 43.2751 mL | |
| 5 mM | 0.8655 mL | 4.3275 mL | 8.6550 mL | |
| 10 mM | 0.4328 mL | 2.1638 mL | 4.3275 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
